Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...

Glenmark and Alkem Labs launched the generic version as well as its Fixed Dose Combination (FDCs) of Empagliflozin in India.

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...

Glenmark launches Empagliflozin and combinations in India under Glempa brand, aiming to improve glycemic control and reduce ...

The biggest advantage of the drug going off patent is that the prices will plummet. The patented medicine, sold as Jardiance, ...

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

The price of empagliflozin, a commonly prescribed diabetes drug, has been slashed by a staggering 90% in India. This ...

Rajeev Juneja, vice chairman and managing director of Mumbai, Indian-based drugmaker Mankind Pharma (NSE: MANKIND), today ...